| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Intestinal absorption primarily occurs via passive diffusion. Excretion is mainly via the kidneys; during hypermagnesemia, up to 97% of magnesium is excreted through the kidneys. The volume of distribution for magnesium ions is approximately 0.2 to 0.4 L/kg/hr. Biological Half-Life It has been reported that the elimination half-life after an overdose of 400 mEq magnesium in adults is 27.7 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
The protein binding rate of magnesium ions is approximately 30%. |
| References | |
| Additional Infomation |
Magnesium acetate tetrahydrate is the hydrated form of anhydrous magnesium acetate, with the chemical formula Mg(CH3COO)2·4H2O. As a magnesium salt, magnesium acetate is one of the most bioavailable forms of magnesium and is highly soluble in water. Magnesium is an essential element for the human body and the second most abundant cation in the body, playing a crucial role in maintaining normal cellular functions, such as ATP production and efficient enzyme activity. Magnesium acetate tetrahydrate can be used as an electrolyte supplement or as a reagent in molecular biology experiments. Magnesium acetate tetrahydrate is the hydrated acetate form of magnesium. Magnesium is a divalent cation, essential for many biochemical processes, including nerve signal transduction, bone mineralization, and muscle contraction. Approximately 350 enzymes involved in glycolysis and the Krebs cycle, cyclic adenosine monophosphate (cAMP) and adenosine triphosphate (ATP) production, cell signal transduction, and protein and nucleic acid synthesis depend on magnesium. See also: Magnesium ions (with active moiety)... See more...
Drug Indications Used as a magnesium salt laxative to prevent constipation. When used in combination with aluminum salts that can cause intestinal retention, it can produce a synergistic effect, restoring normal intestinal function. Magnesium acetate tetrahydrate, when mixed with glucose and other salts to form an intravenous infusion, can serve as a source of water and electrolytes. This injection can be used for patients with carbohydrate or magnesium deficiency, insulin hypoglycemia, constipation, or gestational hypertension. Mechanism of Action Magnesium ions stabilize the adenylate cyclase complex through electrostatic interactions, enhancing its catalytic activity and cAMP production. They also regulate phosphorylation levels in various pathways by forming transition states of phosphotransferase reactions through protein kinases and stabilize the binding of ATP to protein kinases through electrostatic interactions. Many metabolic enzymes involved in glycolysis and the tricarboxylic acid cycle depend on magnesium. Magnesium-containing laxatives stimulate intestinal peristalsis by retaining water and increasing stool volume, thereby causing diarrhea. When used as an electrolyte supplement, magnesium acetate tetrahydrate can induce diuresis and produce metabolic alkalization. Magnesium ions enhance the responsiveness of arteries to vasoconstrictors, promote vasoconstriction, and increase peripheral resistance, potentially leading to increased blood pressure by competing with calcium ions in the vascular system. Magnesium ions also regulate the movement of other ions across cell membranes by acting as ligands for the N-methyl-D-aspartate receptor. Pharmacodynamics Magnesium is an essential cofactor for many enzymatic reactions, such as protein synthesis and ATP production. It is also involved in the adenylate cyclase pathway and the tyrosine kinase signaling pathway. Magnesium may also play a role in regulating glucose metabolism. It is an essential cation for many biochemical processes, including nerve signaling, bone mineralization, and muscle contraction. |
| Molecular Formula |
C4H14MGO8
|
|---|---|
| Molecular Weight |
214.4542
|
| Exact Mass |
214.054
|
| CAS # |
16674-78-5
|
| Related CAS # |
Acetic acid potassium 99%;127-08-2;Acetic acid;64-19-7;Acetic acid lead;546-67-8
|
| PubChem CID |
134717
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.454
|
| Boiling Point |
117.1ºC at 760 mmHg
|
| Melting Point |
72-75 °C(lit.)
|
| Vapour Pressure |
13.9mmHg at 25°C
|
| Index of Refraction |
n20/D 1.358
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
25.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Mg+2].[O-]C(C([H])([H])[H])=O.[O-]C(C([H])([H])[H])=O.O([H])[H].O([H])[H].O([H])[H].O([H])[H]
|
| InChi Key |
XKPKPGCRSHFTKM-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C2H4O2.Mg.4H2O/c2*1-2(3)4;;;;;/h2*1H3,(H,3,4);;4*1H2/q;;+2;;;;/p-2
|
| Chemical Name |
magnesium;diacetate;tetrahydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~466.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6631 mL | 23.3155 mL | 46.6309 mL | |
| 5 mM | 0.9326 mL | 4.6631 mL | 9.3262 mL | |
| 10 mM | 0.4663 mL | 2.3315 mL | 4.6631 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.